Saturday 7 November 2026 Export KRSA’s income statement to Excel — free account

Korsana Biosciences, Inc.

KRSA Healthcare Biotechnology

Revenue: −43.2%
EPS: −272.7%
Free cash flow: −184.7%

Quarter to June 2026, against a year earlier

Operating cash flow growth 3 yrs

30.77 0.34 +1.12%

Follow KRSA

Alert me

Market cap: $1.4B
P/E: 0.0×
Fwd P/E: −2.5×
Dividend yield: —
F-score: n/a
Altman Z: −36.29
Beneish M: −1.95
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 1,390.00

Revenue ttm 2.07

Net income ttm (6.71)

Free cash flow ttm (4.52)

Net debt Q (1.39)

Valuation

P/E 0.00

Forward P/E (2.48)

Price / sales 9.01

Forward P/S Powerpack

Price / FCF 0.00

Price / book 3.67

Financial health

Current ratio Q 0.82

Debt / equity Q 0.00

Interest coverage Q (102.94)

Growth

Revenue growth Q −43.24%

Operating income growth Q −5.92%

EPS, this year +10.45%

EPS, next year A +17.50%

Revenue, next year A −46.96%

EPS, past 5 yrs —

EPS, next 5 yrs A +59.52%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 55.81%

10-year low 10-year high

P/B against its own 10 years 97.78%

10-year low 10-year high

EV/Sales against its own 10 years 71.45%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	8	3	3	1
Receivables	—	1	1	—
Inventory	—	—	—	—
Other	0	0	0	0
	8	4	5	2

	2023	2024	2025	Q'26
Payables	1	0	1	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	2	1	1	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	(14.38%)	(19.27%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(31.33%)	(4.56%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.78 Actual −3.19

−3.55 −2.77 −1.98 −1.20 −0.42

Q3 FY26 Miss −2.41

Q4 FY26 — Mar 29

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY26	−0.78	−3.19	Miss by 2.41
Q4 FY26	−0.86	—	Reports 29 March 2027

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(5.32)	(2.87)	—	—	—
’25	(3.92)	(0.77)	(2.10)	(1.44)	(7.77)
’24	(4.34)	(3.71)	(2.03)	1.54	(8.47)
’23	(22.39)	(12.81)	19.03	(4.82)	(15.74)
’22	(41.99)	(43.39)	(33.59)	(22.39)	(141.36)
’21	(55.02)	(62.98)	(36.39)	(33.59)	(184.74)
’20	(102.17)	(97.97)	(82.57)	(76.98)	(358.29)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	0	0	1	1	2
’24	—	—	0	2	2
’22	1	0	—	1	0
’21	0	3	0	1	4
’20	1	1	0	0	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(1)	(1)	0	(2)	(3)
’24	(2)	(1)	(2)	0	(4)
’23	(6)	(7)	(7)	(2)	(21)
’22	(13)	(11)	(10)	(7)	(41)
’21	(14)	(6)	(8)	(9)	(37)
’20	(29)	(14)	(15)	(14)	(72)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(1)	(1)	0	(2)	(3)
’24	(2)	(1)	(2)	0	(4)
’23	(6)	(7)	(7)	(2)	(21)
’22	(13)	(11)	(10)	(7)	(41)
’21	(13)	(6)	(8)	(9)	(35)
’20	(31)	(14)	(15)	(13)	(72)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	5	2	4	0	—	2	2	2		(12.1%)	1	1	—	(27.2%)
	Gross margin, %	0.00	0.00	0.00	100.00	100.00	100.00	100.00	—	100.00	100.00	100.00		+100.0 pt	Powerpack Korsana Biosciences, Inc.’s next three years, line by line Analysts expect revenue to shrink 27.2% a year to 2028 — slower than the −12.1% of the last 6 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(64)	(94)	(115)	(123)	(78)	(52)	(18)	(13)	(3)	(4)	(7)		(27.5%)
	EBT margin, %	0.00	0.00	0.00	(2,729.27)	(3,388.59)	(1,310.17)	(6,143.43)	0.00	(152.85)	(170.11)	0.00		(170.1) pt
	Net income	(64)	(94)	(115)	(123)	(78)	(52)	(44)	(5)	(3)	(4)	(7)		(27.5%)
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	23.04	10.57	14.09	0.96	0.00	5.56	4.56	0.00		n/m
	Earnings	(2.32)	(3.43)	(589.13)	(628.41)	(358.29)	(184.74)	(141.36)	(15.74)	(8.47)	(7.77)	(11.73)		+14.4%
	Cash flow	(1.82)	(2.96)	(498.48)	(522.57)	(333.75)	(130.56)	(130.79)	(63.59)	(12.04)	(7.29)	(7.33)		+16.7%
	Capex	0.00	(0.05)	(17.58)	(34.33)	0.08	5.21	0.00	0.00	0.00	0.00	(0.12)		n/m
	Free cash flow	(1.82)	(3.02)	(516.06)	(556.90)	(333.66)	(125.35)	(130.79)	(63.59)	(12.04)	(7.29)	(7.45)		+16.7%
	Book value	(0.25)	(0.31)	(53.40)	499.64	273.91	172.49	33.66	33.79	24.60	19.98	8.37		n/m
	Shares, m	27	27	0	0	0	0	0	0	0	0	1		(36.6%)
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	—	0.00	0.00	0.00		0.0
	P/S	—	—	—	0.00	40.53	17.09	13.50	—	2.78	1.95	9.01		12.6
	P/B	—	—	—	0.76	1.56	1.40	2.79	—	0.92	0.44	3.67		1.3
	EV/Sales	—	—	—	0.00	16.83	3.40	7.30	—	1.67	0.39	8.34		4.9
	EV/FCF	—	—	—	0.19	(0.53)	(0.38)	(0.40)	—	(1.70)	(0.43)	(3.82)		(0.5)
Cash, $m
Cash, $m	Operating cash flow	(50)	(81)	(98)	(102)	(72)	(37)	(41)	(21)	(4)	(3)	(4)		(26.0%)
	Capex	(1)	(1)	(3)	(7)	0	1	—	—	—	—	0		n/m
	Free cash flow	(50)	(83)	(101)	(109)	(72)	(35)	(41)	(21)	(4)	(3)	(5)		(26.0%)
Balance, $m
Balance, $m	Working capital	(10)	(13)	(17)	83	42	44	7	6	4	4	0		n/m
	Net debt	—	—	—	(95)	(54)	(54)	(13)	(8)	(3)	(3)	(1)		(43.0%)
	Shareholders’ equity	(7)	(9)	(10)	98	59	48	10	11	9	9	5		n/m
Returns, %
Returns, %	ROA	(1,360.17)	(2,010.10)	(1,790.88)	(126.89)	(51.55)	(59.12)	(113.88)	(33.47)	(26.64)	(36.07)	(82.29)		+1,324.1 pt
	ROIC	0.00	0.00	0.00	(2,757.52)	(996.29)	0.00	0.00	(217.77)	(40.36)	(53.18)	(115.40)		(53.2) pt
	ROE	829.25	1,225.50	1,212.41	(281.86)	(98.97)	(95.87)	(150.19)	(48.42)	(30.36)	(39.34)	(98.22)		(868.6) pt
People
People	Employees	—	—	143	94	94	32	16	1	1	1	—		(50.8%)
	Revenue/emp, $m	—	—	0.00	0.05	0.02	0.12	0.02	0.00	2.00	2.07	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025 · fundamentals updated 2 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TYRA Tyra Biosciences, Inc.	$1.4B	— (loss-making)	—	—	n/m	−31.34% (below 0%: shrinking)	0.00%	0.00%	Compare
AAPG Ascentage Pharma Group International - Unsponsored ADR	$1.4B	—	—	—	—	+17.74% (above 0%: growing)	—	—	Compare
OCUL Ocular Therapeutix, Inc.	$1.4B	— (loss-making)	— (loss-making)	+0.12% (above 0%: growing)	n/m	−25.35% (below 0%: shrinking)	85.08%	(609.34%)	Compare
KRSA Korsana Biosciences, Inc.	$1.4B	— (loss-making)	— (loss-making)	−43.24% (below 0%: shrinking)	n/m	−184.69% (below 0%: shrinking)	100.00%	0.00%
ANAB AnaptysBio, Inc.	$1.4B	— (loss-making)	220×	−7.98% (below 0%: shrinking)	n/m	−141.60% (below 0%: shrinking)	100.00%	(135.53%)	Compare
GPCR Structure Therapeutics Inc. Sponsored ADR	$1.4B	— (loss-making)	—	—	n/m	−119.15% (below 0%: shrinking)	0.00%	0.00%	Compare
DMRA Galecto, Inc.	$1.4B	24.7×	—	—	n/m	−877.51% (below 0%: shrinking)	0.00%	0.00%	Compare
MLYS Mineralys Therapeutics, Inc.	$1.4B	— (loss-making)	—	—	n/m	−7.91% (below 0%: shrinking)	—	0.00%	Compare
TSHA Taysha Gene Therapies, Inc.	$1.3B	— (loss-making)	— (loss-making)	+206.77% (above 0%: growing)	n/m	−100.28% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$1.4B	—	—	+0.12%	—	−65.81%	42.54%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 15 October 2026

Ownership

Directors and executive officers, together 31.04%

Entities Affiliated with Fairmount 19.99%

Tomas Kiselak 19.99%

Entities Affiliated with Venrock Healthcare Capital Partners 9.99%

Entities Affiliated with TCGX 9.99%

Nimish Shah 9.99%

FMR LLC 6.90%

Entities Affiliated with Wellington Management 6.10%

Entities Affiliated with J.P. Morgan Life Sciences Private Capital 5.90%

Entities Affiliated with Janus Henderson Investors 5.15%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Korsana Biosciences, Inc. (KRSA) Latest News

5 Nov

Impact 3 · 7:00 AM · GlobeNewswire

Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update

2 Oct

Impact 3 · 8:06 AM · Simply Wall St.

Korsana Biosciences (KRSA) At $31.20 Leaves Valuation Questions On A Sharp 2026 Run

8 Sep

Impact 5 · 4:05 PM

Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million

20 Apr

Impact 4 · 10:15 AM

Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s Pipeline

1 Apr

Impact 4 · 7:05 AM · Business Wire

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

23 Feb

Impact 4 · 6:53 AM · Zacks Small Cap Research

CYCN: Positive Feedback from FDA Sets Stage for Phase 2 Trial of CYC-126 in 2H26

17 Feb

Impact 4 · 7:00 AM · GlobeNewswire

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

2 Feb

Impact 4 · 7:14 AM · Zacks Small Cap Research

CYCN: Engineering a Reset; Initiating Coverage of Cyclerion Therapeutics…

5 Jan

Impact 4 · 4:01 PM · GlobeNewswire

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

1 Dec

Impact 3 · 8:40 AM · MT NewswiresSimply Wall St.Simply Wall St.MT NewswiresZacksGuruFocus.comMT Newswires

Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal

11 Nov

Impact 3 · 9:17 AM · Simply Wall St.

Insider Stock Buying Reaches US$525.0k On Cyclerion Therapeutics

23 Sep

Impact 4 · 4:01 PM · GlobeNewswire

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

5 Feb

Impact 3 · 3:06 PM · Simply Wall St.

3 US Penny Stocks With Market Caps Over $10M To Consider

17 Dec

Impact 4 · 8:08 AM · GlobeNewswire

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

7 Aug

Impact 4 · 7:00 AM · GlobeNewswire

Regina Graul, Ph.D., Promoted to Chief Executive Officer

4 Dec

Impact 4 · 8:00 AM · GlobeNewswire

Cyclerion Appoints Regina Graul, Ph.D., as President

30 Nov

Impact 4 · 6:16 PM · GlobeNewswire

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

28 Nov

Impact 3 · 9:23 AM · Simply Wall St.

Cyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With Losses

31 Jul

Impact 4 · 7:00 AM · GlobeNewswire

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

12 May

Impact 4 · 2:59 PM · Benzinga

Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New Investors

11 May

Impact 4 · 6:00 PM · GlobeNewswire

Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

Impact 4 · 6:00 PM · GlobeNewswire

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

Korsana Biosciences, Inc.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Korsana Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 15 October 2026

Ownership

Korsana Biosciences, Inc. (KRSA) Latest News

5 Nov

2 Oct

8 Sep

20 Apr

1 Apr

23 Feb

17 Feb

2 Feb

5 Jan

1 Dec

11 Nov

23 Sep

5 Feb

17 Dec

7 Aug

4 Dec

30 Nov

28 Nov

31 Jul

12 May

11 May

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Korsana Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 15 October 2026

Ownership

Korsana Biosciences, Inc. (KRSA) Latest News

5 Nov

2 Oct

8 Sep

20 Apr

1 Apr

23 Feb

17 Feb

2 Feb

5 Jan

1 Dec

11 Nov

23 Sep

5 Feb

17 Dec

7 Aug

4 Dec

30 Nov

28 Nov

31 Jul

12 May

11 May

Stockrow Weekly